Maxim Group Thinks Soliton’s Stock is Going to Recover

By Jason Carr

Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Soliton (SOLYResearch Report) yesterday and set a price target of $22.00. The company’s shares closed last Thursday at $7.67, close to its 52-week low of $6.64.

According to, Vendetti is a 4-star analyst with an average return of 4.3% and a 46.7% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Ra Medical Systems, and Sensus Healthcare.

Currently, the analyst consensus on Soliton is a Moderate Buy with an average price target of $19.00, implying a 139.6% upside from current levels. In a report issued on June 16, Roth Capital also maintained a Buy rating on the stock with a $16.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.97 and a one-year low of $6.64. Currently, Soliton has an average volume of 225.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Soliton, Inc. is a medical development company. It develops healthcare technological devices for medical and cosmetic treatments. The firm’s devices generate planar acoustic waves or shock waves in cosmetic surgical procedures, aesthetic surgical procedures, and dermatology procedures for treatments. The company was founded by Walter V. Klemp & Christopher Capelli and is headquartered in Houston, TX.